Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

ABSTRACT: The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐risk chronic myelomonocytic leukemia (higher‐risk CMML), or...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaofei, Friedlander, Sharon, Kupperman, Erik, Sedarati, Farhad, Kuroda, Shingo, Hua, Zhaowei, Yuan, Ying, Yamamoto, Yuka, Faller, Douglas V., Haikawa, Kazue, Nakai, Katsuhiko, Bowen, Sharon, Dai, Yi, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212745/
https://www.ncbi.nlm.nih.gov/pubmed/33503305
http://dx.doi.org/10.1111/cts.12972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212745/
https://www.ncbi.nlm.nih.gov/pubmed/33503305
http://dx.doi.org/10.1111/cts.12972

Ejemplares similares